European journal of haematology · 2026
Elevated Risks for Depression and Anxiety Following Diagnosis of Multiple Myeloma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rydahl Klara F K, Øvlisen Andreas Kiesbye, Horsbøl Trine Allerslev, Möller Sören, Nielsen Lene Kongsgaard, Østergaard Søren Dinesen, El-Galaly Tarec Christoffer, Rohde Christopher
Аннотация
BACKGROUND: Patients with multiple myeloma (MM) may be particularly vulnerable to depression and anxiety following diagnosis due to high disease burden, treatment-related side effects, and the incurable nature of the disease.
METHODS: In this nationwide population-based cohort study, we used Danish population-based registries to investigate the risk of depression and anxiety in patients with MM (symptomatic MM and smoldering MM) compared with age- and sex-matched individuals from the general population.
RESULTS: A total of 3861 patients with MM and 19 305 matched comparators were included (median age 73 years; 59% male). During follow-up, depression and/or anxiety occurred in 315 MM patients (8.2%) and 660 comparators (3.4%). MM was associated with a substantially increased risk of depression and/or anxiety (adjusted HR 2.56, 95% CI 2.23-2.94). The association was strongest among patients with symptomatic MM (adjusted HR 2.63, 95% CI 2.21-3.12) but remained elevated among patients with smoldering MM (adjusted HR 1.44, 95% CI 1.10-1.87). The association was strongest during the first year following diagnosis and attenuated over time.
CONCLUSION: These findings demonstrate an elevated risk of depression and/or anxiety among patients with both symptomatic and smoldering MM and highlight the need for increased awareness of psychological morbidity, particularly during the first year after diagnosis.
METHODS: In this nationwide population-based cohort study, we used Danish population-based registries to investigate the risk of depression and anxiety in patients with MM (symptomatic MM and smoldering MM) compared with age- and sex-matched individuals from the general population.
RESULTS: A total of 3861 patients with MM and 19 305 matched comparators were included (median age 73 years; 59% male). During follow-up, depression and/or anxiety occurred in 315 MM patients (8.2%) and 660 comparators (3.4%). MM was associated with a substantially increased risk of depression and/or anxiety (adjusted HR 2.56, 95% CI 2.23-2.94). The association was strongest among patients with symptomatic MM (adjusted HR 2.63, 95% CI 2.21-3.12) but remained elevated among patients with smoldering MM (adjusted HR 1.44, 95% CI 1.10-1.87). The association was strongest during the first year following diagnosis and attenuated over time.
CONCLUSION: These findings demonstrate an elevated risk of depression and/or anxiety among patients with both symptomatic and smoldering MM and highlight the need for increased awareness of psychological morbidity, particularly during the first year after diagnosis.